Skip to main content
. Author manuscript; available in PMC: 2012 Nov 22.
Published in final edited form as: J Am Coll Cardiol. 2011 Nov 22;58(22):2270–2278. doi: 10.1016/j.jacc.2011.08.041

Table 1. Characteristics of patients demonstrating clinical similarity between Recovered and Dependent groups prior to VAD implantation, in both Test and Validation cohorts.

Duration of congestive heart failure (CHF) was defined as the time in days from original presentation with heart failure until VAD placement. Days on VAD was defined as time to VAD explant (Recovered group) or Transplantation (Dependent group). All patients on pulsatile VAD support were on Thoratec (Pleasanton CA) extracorporeal devices. PCWP and cardiac index measured immediately prior to VAD implantation, while on inotropes.

Clinical Characteristics At Baseline
Test Cohort Validation Cohort NonFailing Controls Test Vs Validation Cohorts All VAD Vs NonFailing Controls
Recovered Dependent p Value Recovered Dependent p Value p Value p Value
Number of Patients 7 7 7 7 7
Age (years) 40±12 42±15 NS 27±8 33±9 NS 36±10 NS NS
Percent Ischemic 0 0 NS 0 0 NS 0 NS NS
Inotropic Support 100% 100% NS 85% 100% NS 0 NS <0.001
Intraaortic Balloon Pump 43% 57% NS 43% 14% NS 0 NS <0.001
Other Mechanical Support (TandemHeart) 0% 0% NS 14% 14% NS 0 NS <0.001
Percent Male 50% 50% NS 71% 71% NS 50% <0.04 NS
EF Prior to VAD (%) 18±5 15±5 NS 18±5 17±5 NS 65±10 NS <0.001
LVEDd Prior to VAD (cm) 6.0±0.8 6.2±0.8 NS 7.0±1.0 7.0±1.0 NS Data not available <0.02 Data not available
PCWP Prior to VAD (mm Hg)* 26±9 27±10 NS 27±5 27±11 NS Data not available NS Data not available
Cardiac Index Prior to VAD (L/min/m2)* 1.9±0.89 2.0±0.73 NS 1.6±0.24 1.8±0.41 NS Data not available NS Data not available
Duration of CHF (days) 62±49 75±58 NS 680±1117 771±802 NS NA <0.001 NA
Type of VAD (% Rotary) 14% 14% NS 71% 42% NS NA <0.01 NA
Days on VAD 53±31 61±29 NS 433±250 369±167 NS NA <0.001 NA
Clinical Characteristics At 6 Month Follow Up Post VAD Explantation
Test Cohort Validation Cohort NonFailing Controls Test Vs Validation Cohorts
Recovered Dependent p Value Recovered Dependent p Value p Value
Number of Patients 5 5 7 7 NA
Betablocker use while on VAD 67% 83% NS 100% 85% NS NA NS
ACE Inhibitor use while on VAD 83% 83% NS 85% 85% NS NA NS
EF at 6 months post explantation (%) 55±5 N/A - 43±11 N/A NA <0.04

NS: not significant;

NA: Not applicable.

HHS Vulnerability Disclosure